Compare SII & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SII | TMDX |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 2011 | 2019 |
| Metric | SII | TMDX |
|---|---|---|
| Price | $106.50 | $72.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $135.82 | $98.73 |
| AVG Volume (30 Days) | 86.9K | ★ 713.8K |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | $35.89 | $22.57 |
| Revenue Next Year | N/A | $17.85 |
| P/E Ratio | ★ $63.42 | $119.75 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $78.79 | $60.11 |
| 52 Week High | $169.63 | $156.00 |
| Indicator | SII | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 31.82 | 36.32 |
| Support Level | $102.24 | $66.64 |
| Resistance Level | $111.40 | $79.60 |
| Average True Range (ATR) | 3.41 | 3.93 |
| MACD | -0.83 | -0.62 |
| Stochastic Oscillator | 17.69 | 26.43 |
Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.